An Alphabet-backed startup is poised to begin clinical trials of its first artificial intelligence-designed drug by year-end.

Isomorphic was spun out of Google’s AI research arm Google DeepMind in 2021, but remains a wholly owned subsidiary of its ...

Eli Lilly and Merck & Co. are partnering with Purdue University to launch the Young Institute Pharmaceutical Manufacturing ...

Just as quickly, investors are losing their appetite for the trade. After a disappointing trial of a new Novo Nordisk drug ...

Shares of Schrödinger soared by 15% mid-day Tuesday as the company, known for leveraging quantum mechanics in medicine and material design, embraces artificial intelligence (AI) to enhance its drug ...

Drugs developed by Alphabet’s drug discovery subsidiary and designed by artificial intelligence are expected to head to trial by the end of the year, according to a Google (GOOGL) executive.

In this article, we are going to take a look at where Eli Lilly and Company (NYSE ... “See, I’m thinking that Lilly’s wonder drug Mounjaro, also known as Zepbound, has way too many potential ...

Delve into the increasingly dynamic landscape of ALS treatment development with thirteen companies advancing candidates in ...

Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA ... progressed on a prior aromatase inhibitor (AI), with or without a CDK4/6 inhibitor.

Eli Lilly has backed away from plans to file Alzheimer's drug donanemab in the first quarter ... in both donanemab and the unique study design," said Skovronsky. "Given the impact of this ...